Watch EWTX. Know when insiders buy.
One email the day a filing lands. Free.
EWTX
Edgewise Therapeutics, Inc.
44.40
+1.50 +3.50%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.8BP/E —DIV YIELD —FCF YIELD -3.29%REV TTM —NET INCOME −$197.2MNET CASH $72.3M52W 13.70 – 48.35SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$61.9M | −$57.3M | — | -0.53 | −$42.5M | $32K | −$42.5M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$54.1M | −$49M | — | -0.46 | −$42.5M | $260K | −$42.8M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$56M | −$50.2M | — | -0.48 | −$38.6M | $73K | −$38.7M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$46.9M | −$40.7M | — | -0.39 | −$34.8M | $89K | −$34.9M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$42.6M | −$36.1M | — | -0.34 | −$32.6M | $50K | −$32.6M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$46M | −$40.8M | — | -0.43 | −$37.9M | $44K | −$37.9M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$45.5M | −$39.7M | — | -0.42 | −$27M | $274K | −$27.2M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$40.4M | −$34.1M | — | -0.36 | −$27.4M | $520K | −$27.9M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$38.1M | −$31.5M | — | -0.34 | −$26.1M | $221K | −$26.3M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$34.8M | −$28.5M | — | -0.33 | −$28.6M | $297K | −$28.9M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$33.9M | −$30.1M | — | -0.47 | −$26.8M | $161K | −$27M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$29.5M | −$25.7M | — | -0.41 | −$22.1M | $457K | −$22.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$191.4M | −$167.8M | — | -1.63 | −$143.8M | $256K | −$144.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$158.8M | −$133.8M | — | -1.45 | −$109M | $1.3M | −$110.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$114.4M | −$100.2M | — | -1.57 | −$91.9M | $5.7M | −$97.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$71.7M | −$67.6M | — | -1.26 | −$52.6M | $5.5M | −$58.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$43.2M | −$42.8M | — | -1.14 | −$33.5M | $668K | −$34.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$17.2M | −$17.1M | — | -23.17 | −$14.6M | $203K | −$14.8M | — | — |
Every number comes from Edgewise Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.